Lipolysis
Glucagon Adrenal disorders Phosphorylase in liver be recognized as a second messenger mediating a variety of hormonal effects.2 5 The second messenger concept is illustrated in figure 1. According to this concept, the first messengers, the hormones themselves, travel from their cells of origin to the cells of their target tissues to cause therein an alteration in the intracellular level of a second messenger. It may be noted that in some cases, as in neurohumoral transmission within the autonomic nervous system, and also in the case of pancreatic glucagon acting on the pancreatic beta cells,6 the first messenger may not have far to travel. (The classical definition of hormones as agents which are transported via the bloodstream seems unnecessarily restrictive from the biochemical point of view. A potentially more useful definition was proposed some years THE SECOND MESSENGER SYSTEM INVOLVING ADENYL CYCLASE Figure 1 ago by Huxley,7 who suggested that hormones be regarded as agents which transfer information from one set of cells to another for the good of the cell population as a whole.)
The formation of cyclic AMP from ATP (adenosinetriphosphate) is catalyzed by adenyl cyclase, which in at least some cases is located in the cell membrane.8'9 Adenyl cyclase is affected by different hormones in different tissues and is thus seen to function both as a discriminator for environmental signals and as a signal generator. By this mechanism, the initial extracellular signal, represented by the first messenger, is changed to a signal (the second messenger) which is capable of acting within the cell. This signal may undergo amplification in a variety of ways, the ultimate response depending on the enzymatic profile of the type of cell involved. The cybernetic aspects of hormone action have been discussed more extensively by Hechter and his associates.10 11 The only second messenger which has been identified to date is cyclic AMP, but it seems likely that other second messengers will eventually be discovered. The possibility that other cyclic nucleotides may function in this capacity will be discussed in a later section.
Before going on to some of the newer data, which may be of special interest to those engaged in cardiovascular research, a brief review of some of the early experiments which led to the discovery of cyclic AMP may be worthwhile.
Early Experiments
One of the most important components of the hyperglycemic response to epinephrine and glucagon is an increase in the rate of THE BIOLOGICAL ROLE OF CYCLIC AMP release of glucose from the liver. After it was established that liver slices were suitable for the study of this effect, one of the first questions to be asked was whether glucose was pumped out of the iver cells when the hormones were added or did it accumulate and overflow because of an increased rate of production? The latter conclusion was suggested by experiments which showed that cells stimulated by epinephrine or glucagon contained much more glucose than the controls.12 That the breakdown of glycogen in response to these hormones was the result of phosphorolysis rather than hydrolysis was indicated by several lines of evidence, among them the finding that the glycogenolysis was associated with the formation of monosaccharides instead of the larger units which would have been expected had amylase activity been stimulated. Figure 2 shows the results of some experiments involving the measurement of hexose monophosphate levels in liver slices. These experiments showed that the concentrations of both glucose-i-phosphate and glucose-6-phosphate increased when the hormones were Analysis of glucose-i-phosphate (G-1-P) and glucose-6-phosphate (G-6-P) in liver slices. Isotopic hexose phosphates were formed by incubation of liver slices with radioactive inorganic phosphate. After addition of nonlabeled carrier, the intermediates were purified and radioactivity was determined. Modified from Sutherland.12 Circulation, Volume XXXVII, added. Analysis of these and other data led to the conclusion that phosphorylase, rather than phosphoglucomutase or glucose-6-phosphatase, was rate-limiting in the conversion of glycogen to glucose, and that glucagon and epinephrine acted somehow to stimulate the activity of this enzyme.13 This conclusion was probably premature, in view of the later discovery of glycogen synthetase,'4 but it nevertheless seems to have been substantially correct.
Further investigation of the hormonal effect on the phosphorylase system showed that the concentration of active enzyme in liver slices was increased by glucagon and epinephrine. This was demonstrated directly by measurements of phosphorylase activity in homogenates or extracts prepared from slices which had been incubated with and without the hormones.'5 The level of phosphorylase in liver slices was shown to represent a balance between enzymatic inactivation and activation, and the change from the inactive to the active form in response to the hormones was found to be rapid. At this point reactivation could be obtained only in slices and not in broken cell preparations.
The inactivation process could be studied in such preparations, however, and liver phosphorylase and the enzyme inactivating it were prepared in purified form from dog liver. 16 The product of the reaction, inactive phosphorylase, differed from muscle phosphorylase b in that its activity was not greatly increased in the presence of 5'-AMP. The other product of the reaction was found to be inorganic phosphate, the formation of which paralleled the formation of inactive phosphorylase (2 moles of phosphate per mole of enzyme), with no apparent change in the molecular weight of the protein. These findings were just recently confirmed.'7 These and other experiments led to the conclusion that the inactivating enzyme was a relatively specific phosphatase.
This conclusion in turn suggested that the activation of phosphorylase might consist of a phosphorylation of the inactive enzyme.
Experiments were then designed to see if Effect of epinephrine (E) and glucagon (G) on 32P incorporation into dog liver slice phosphorylase (L. P. It may be useful in this regard to consider briefly the studies which have been carried out with aspartate transcarbamylase. The enzyme from E. coli has been extensively purified and its molecular weight determined.61 It has been found that under appropriate conditions the enzyme can be dissociated into two types of subunits. One subunit possesses all of the catalytic activity of the undenatured enzyme but is not subject to inhibition by CTP, which in E. coli is the normal allosteric inhibitor of the enzyme. The other subunit has no catalytic activity but possesses all of the binding sites for CTP. These elegant studies were carried out by Gerhart and Schachman.6' In certain other species, however, it has not yet been possible to purify aspartate transcarbamylase very extensively and still retain the enzyme's sensitivity to allosteric inhibition.62 The parallel between these studies and our own experience with adenyl cyclase has seemed to us striking, or at least suggestive. These and other considerations, including the cellular location of adenyl cyclase, have in any event led us to regard our own view as a reasonable one, although it is obviously far from established.
On the other side of the membrane there is the problem of how cyclic AMP acts to produce the effects which it is known to be capable of producing. In the several cases which have been studied in detail such as phosphorylase activation,63 ATP is a component of the reaction which is affected. In certain other cases, such as the permeability changes which are seen in the toad bladder, virtually nothing is known about the basic nature of the process involved.4 It is perhaps not too much to hope, however, that the identification of cyclic AMP as the mediator of these responses may lead to a clearer understanding of the responses themselves.
At this point we might briefly consider two of the responses which have just recently been placed in the "well-established" category. These are the lipolytic response of adipose tissue to a variety of hormones and the steroidogenic response of the adrenal cortex to ACTH. Following this we will turn to the cardiovascular system, with emphasis on the positive inotropic response to the catecholamines. Finally we would like to make a few general remarks, including a brief discussion of the possible clinical implications of this research.
The Lipolytic Response
Lipolysis (the breakdown of triglycerides to free fatty acids and glycerol) has been studied in detail in the rat epididymal fat pad and has been found to be stimulated by the catecholamines, ACTH, glucagon, TSH, and several other hormones.64 The lipolytic actions of these hormones can be antagonized by a variety of agents, including insulin, the prostaglandins, nicotinic acid, and adrenergic blocking agents. 64 65 The lipolytic response was of great interest from the standpoint of the biological role of cyclic AMP, for all of the hormones with lipolytic activity were known or suspected to have actions mediated by cyclic AMP in the tissues with which they were more commonly associated ( Adenyl cyclase activity in preparations of lysed isolated fat cells was stimulated by THE BIOLOGICAL ROLE OF CYCLIC AMP rine,67 and the effect of epinephrine was antagonized by pronethalol. 67 Perhaps the most extensively studied criterion has been the second, that is, the relationship between intracellular cyclic AMP levels and lipolysis. Both lipolysis and the concentration of cyclic AMP were increased in fat pads incubated with epinephrine, and the degree to which lipolysis was stimulated was directly related to the level of cyclic AMP in the cell (except at very high levels, where another component of the lipolytic mechanism was saturated and cyclic AMP was no longer rate-limiting) .23 In addition, caffeine, which had been shown by Vaughan and Steinberg68 to act synergistically with epinephrine on lipolysis, thus satisfying our third criterion, was found to act in the same fashion on cyclic AMP formation.23 The effect of epinephrine on cyclic AMP levels preceded any detectable increase in the rate of release of free fatty acids (FFA) ,23 and the effects of /3-adrenergic blocking agents on lipolysis were reflected in their effects on cyclic AMP levels.23 The a-adrenergic blocking agents, which in high concentrations may act as noncompetitive antagonists of a variety of lipolytic hormones,09 probably act by interfering with the action rather than the formation of cyclic AMP. Phentolamine, for example, does not prevent the accumulation of cyclic AMP in the epididymal fat pad in response to catecholamines,40 but Aulich and associates70 have shown that it does antagonize the lipolytic action of the dibutyryl derivative of cyclic AMP. Interference with the action of cyclic AMP is probably not the mechanism of a-adrenergic blockade in general, but several anomalous actions of the a-adrenergic blocking agents may be understandable on this basis. These would include effects of dihydroergotamine in the rat liver,7' and, possibly, in the rat uterus as well.72
This does not exclude the possibility that in some tissues these drugs may interfere with the formation of cyclic AMP, either in addition to or instead of an action at some later point. Such an effect of ergotamine, for example, was seen in dog liver homogenates. The interactions among lipolytic and antilipolytic agents, the cyclic AMP mechanism, and the lipolytic process are illustrated in figure 6 . The lipolytic hormones stimulate adenyl cyclase and thus promote increased intracellular levels of cyclic AMP. The /3-adrenergic blocking agents interfere with the action of the catecholamines on adenyl cyclase but have not been found to antagonize ACTH or glucagon (although it is possible that this might occur with high enough concentrations). The methylxanthines act as would be predicted for phosphodiesterase inhibitors, which indeed they are in adipose tissue.67 As discussed above, the mechanisms by which insulin and the prostaglandins act to lower cyclic AMP levels are not known.
Cyclic AMP, once elevated, must then act in some way to increase the activity of triglyceride lipase, which is the rate-limiting step in triglyceride breakdown. Rizack79 has reported the stimulation of such a system in cell-free preparations, although this required unusually stringent conditions. Despite the evidence implicating cyclic AMP as the second messenger in this response, it is clear that much work remains to be done before all of the steps in the stimulation of lipolysis are completely worked out.
The Steroidogenic Response
The steroidogenic action of ACTH on the adrenal cortex is one of the more intensively studied hormone actions in which cyclic AMP plays a role. All four criteria have been met, and, while the mechanism by which cyclic AMP translates and amplifies the signal carried by ACTH is not entirely clear, it now seems well established that cyclic AMP does the job. As shown schematically in figure 7, ACTH acts specifically with the adenyl cyclase system. Cell-free preparations of adenyl cyclase from rat adrenals and beef adrenal cortex responded to the addition of ACTH with increased cyclic AMP accumulation, while epinephrine and glucagon were without effect. 80 These data satisfy (in part at least) our first criterion.
The second criterion has also been established. Haynes and associates42 found some years ago that the addition of ACTH to beef adrenal slices caused increased cyclic AMP levels (and phosphorylase activation) as well as increased rates of corticoid production. More recently, Grahame-Smith and associates80 have further studied the relationship between cyclic AMP and steroidogenesis in the rat adrenal in vitro and in vivo. Within limits, a direct proportionality was found between the level to which cyclic AMP was increased by ACTH and the amount of steroid hormone produced. The qualitative specificity was also examined in detail, using analogues of ACTH, and the potencies of these analogues in producing increased levels of cyclic AMP were found to be the same as their potencies as steroidogenic agents. Temporally, it was found that cyclic AMP levels were increased in response to ACTH before any increase in the rate of steroidogenesis could be detected.
The finding that ACTH is capable of increasing the concentration of cyclic AMP in the adrenal cortex to, a level higher than necessary for a maximal response80 is similar to the findings with epinephrine in adipose tissue23 and also with glucagon in the liver.8' The physiological significance of this "extra" cyclic AMP seems dubious, for it is unlikely that the plasma levels of the hormones involved ever reach the levels necessary for the production of such high concentrations of cyclic AMP. The phenomenon is nevertheless of some theoretical interest and might even be taken as a good illustration of the pharmacological concept of spare receptors. 82 Bieck and Westermann83 have reported that theophylline does not increase the steroidoCirculation, Volume XXXVII, February 1968 genic effect of ACTH in the rat. Halkerston and associates84 studied this in vitro and found that, although higher concentrations of theophylline were inhibitory, a concentration of 10-3M caused a small but statistically significant potentiation of ACTH. Further experiments showed that the inhibitory effect of theophylline was associated with an inhibition of protein synthesis, which is especially important in this case because of the evidence that protein synthesis is involved in the steroidogenic effect of cyclic AMP. The existence of a "rapidly turning-over protein" has been postulated to account for the inhibitory effects of other inhibitors of protein synthesis. 85 The fourth criterion was initially satisfied in beef adrenal slices by Haynes and associates. 86 The steroidogenic effect of exogenous cyclic AMP has since been demonstrated by a number of investigators in several different species both in vitro and in vivo. These data are reviewed in detail elsewhere. 43' 56 The mechanism by which cyclic AMP acts to stimulate steroidogenesis is unclear at the present time. An important rate-limiting step appears to be the conversion of cholesterol to pregnenolone, and it is this step which seems to be ultimately stimulated by cyclic AMP. 87 The possible participation of a "rapidly turning-over protein" has been mentioned, but the nature of its participation, or the mechanism by which its synthesis might be affected by cyclic AMP is unknown. The recent report by Khairallah 116, 117 and in the rat heart in situl"8 and were found to be elevated in all cases following the administration of epinephrine. The studies in the rat heart, illustrated in figure 9 , revealed that the activation of adenyl cyclase was an extremely rapid process, preceding both the inotropic response Effect of a single dose of epinephrine in the isolated perfused working rat heart. 132 by these data, since Drummond and associates"17 noted a ninefold increase within 1 second of the administration of epinephrine. Namm and Mayer,"s using a biopsy sampling technique, were unable to detect a significance change in cyclic AMP in response to epinephrine in the dog heart in situ. This was found to be due to the delay in freezing the sample. These studies by Namm and Mayer offer an impressive demonstration of the need for rapid fixation in experiments involving the measurement of intracellular cyclic nucleotide levels.
In our own experiments with the isolated perfused working rat heart, the administration of pronethalol was found to prevent the effects of epinephrine on both contractility and cyclic AMP levels.'04 This effect of pronethalol has more recently been demonstrated in the rat heart in situ,"18 and Drummond and associates"7 showed that the activation of phosphorylase b kinase, which is closely related to the level of cyclic AMP, was also blocked by pronethalol. By contrast, IMA, at the highest concentrations which we could use in the working rat heart without producing severe cardiotoxicity, prevented neither the rise in cyclic AMP nor the positive inotropic effect in response to a relatively large dose of epinephrine.'04 This was an important experiment because Burns and associates"9 had reported that a similar concentration of IMA in dogs prevented most of the metabolic responses to isoproterenol but did not affect the inotropic response. Since the metabolic responses were known to be mediated by cyclic AMP, it might have been predicted that in the rat heart IMA would prevent the increase in cyclic AMP in response to epinephrine but not the positive inotropic effect, thereby invalidating the hypothesis that this response is mediated by cyclic AMP. As summarized above, however, this was found not to be the case.
Further stimulated by the findings of Burns and associates,"9 we measured the ability of IMA to prevent the stimulation of adenyl cyclase by isoproterenol in washed particulate preparations from dog heart and liver.5 Pronethalol and IMA were found to be roughly Circulation, Volume XXXVII, February 1968 equipotent in the liver, but IMA was at least 10 times less effective in the heart. This is in line with the physiological data,15' 119 and also with the concept that the fl-receptor is closely associated with (if not an integral component of) the adenyl cyclase system. Other investigators, using a variety of nonworking cardiac muscle preparations,100' 115 120 have shown that IMA is a weak 83-adrenergic blocking agent and that the cardiac effects of small doses of the catecholamines can be completely prevented by relatively large doses of IMA. Kukovetz and Pdch120 studied this in the isolated perfused guinea pig heart and found that the effects of the catecholamines on phosphorylase a levels and contractility were affected similarly by IMA. These and other studies by Kukovetz and PRch12' suggest that in the guinea pig heart the activation of phosphorylase and the enhanced contractile force may be more closely geared than in the rat or dog heart.105 106 Even in this species, however, it was possible to dissociate the two responses by the use of a low concentration of norepinephrine.'2' Moran60 has reported that he and Mayer noted a transient inhibition by IMA of phosphorylase activation in the dog heart in situ in response to norepinephrine, but not in response to isoproterenol. The positive inotropic response was unaffected in either case. Kukovetz and Pdch'2' were unable to dissociate the inotropic response from phosphorylase activation in the guinea pig heart by the use of isoproterenol, even though, as mentioned, they were able to do so by the use of small doses of norepinephrine. They then made the interesting discovery that the cardiac effects of isoproterenol occurred more rapidly than those of norepinephrine, presumably a reflection of the greater potency of isoproterenol in stimulating cardiac adenyl cyclase. 73 The reasons for the lower potency of IMA in the heart are not known. A widely held concept in the past has been that all fl-receptors ( The data in figure 9 illustrate the effect of allowing a single dose of epinephrine to be rapidly pumped through the heart. When the epinephrine is allowed to recirculate, the level of cyclic AMP still rises and falls, but it falls to an intermediate level which is dosedependent.5 This is illustrated in the lower panel of figure 10 . In these experiments the hearts were frozen 5 minutes after the addition of the indicated concentration of epinephrine. By this time the force of contraction had begun to decline due to the increase in rate.'28 Peak contractile force could be maintained by crushing the right atrium and stimulating the heart electrically, but, since this procedure interfered with the rapid freezing of the heart, we chose instead to measure the inotropic effect at its peak, at whatever time this occurred, and these values are shown in the upper panel of figure 10 . The important point to be made here is that the increase in the level of cyclic AMP could not be dissociated from the drug-induced increase in contractile force. The smallest concentrations of epinephrine with which we could obtain a measurable inotropic effect Circulation, Volume XXXVII, February 1968 also caused a significant increase in the intracellular concentration of cyclic AMP. These studies, together with the other studies mentioned in the foregoing paragraphs, have combined to help satisfy our second criterion.
Other cardiac effects produced by the catecholamines, in addition to those already mentioned, include a decrease in glycogen synthetase activity'29' 130 and an increase in myocardial oxygen consumption. The effect on glycogen synthetase seems to be mediated by cyclic AMP,'13 but this effect may be obscured in the beating heart by the opposite effect of decreasing glycogen levels'30' 131 and possibly other factors.'29 Under normal conditions the effect on oxygen consumption may be largely secondary to the increased work of the heart,132 but Challoner and Steinberg133 found that a significant increase in 02 consumption (qO2) could be produced by epinephrine even in nonbeating hearts. On the basis of several lines of evidence, including the demonstration that intracellular FFA levels were increased in these hearts, Challoner and Steinberg suggested that the stimulation of qO2 might be secondary to an increased lipolytic activity. This is supported by the recent finding that lipolytic activity in rat heart homogenates can be stimulated by the addition of cyclic AMP.134 It had been shown previously that cyclic AMP levels increase in response to epinephrine whether the heart is beating or not.5 The mechanism of lipase activation is not well understood, even in adipose tissue,79 but it would now appear that this effect of cyclic AMP may be common to a variety of tissues.'34-136 The requirement for ATP and Mg++ suggests that the basic process may be similar to the activation of phosphorylase. 63 The cardiac effects of large concentrations of glucagon seem to be the same as those of epinephrine,'30 137 including the production of a positive inotropic effect.138 It has recently been shown in the perfused rat heart that these concentrations of glucagon increase the intracellular level of cyclic AMP.139 This effect of glucagon is not likely to be of physiological significance, because of the high concentraCirculation, Volume XXXVII, February 1968 tions required, but it is at least of some theoretical interest. Possibly the inotropic effects of several other hormones which are known to affect cyclic AMP levels in other tissues, such as the effects of histamine'40 and the prostaglandins,'41 may be produced by a similar mechanism. However, there is no direct evidence at the present time that these agents alter the level of cyclic AMP in the heart.
Potentiation by theophylline, our third criterion, was demonstrated for the positive inotropic effect of norepinephrine by Rall and West.'42 This raises the question of whether the positive inotropic response to the methylxanthines by themselves can be related to cyclic AMP. The answer to this question is not known, but it seems likely that at least part of this response is due to the ability of these agents to increase the level of cyclic AMP in the heart by inhibiting phosphodiesterase. Support for this view comes from the recent demonstration by Kukovetz and Pbch35 that imidazole antagonizes the positive inotropic effect of the methylxanthines in the isolated perfused guinea-pig heart. These investigators also found that imidazole could prevent the positive inotropic response to small but not large doses of the catecholamines. These results are exactly what would be predicted if imidazole were to stimulate phosphodiesterase activity in the beating heart, as it has been shown to do in vitro.30 Another interesting piece of evidence in favor of this mechanism of action has been reported by Logan and Cotten,143 who found that the positive inotropic response to theophylline was reversed by ouabain at low temperatures in the same way as the catecholamine response was. Other similarities between the cardiac effects of the catecholamines and the methylxanthines have been emphasized by others.37 ' 144, 145 In general, all of the available evidence is at least compatible with the hypothesis that the positive inotropic response to the methylxanthines is mediated by cyclic AMP. The effect would in this respect be similar to that of the catecholamines, except that the increase in the level of cyclic AMP is brought about by a different mechanism. At the same time there are indications that the methylxanthines may produce at least one additional effect in the heart which may at times obscure the effects of inhibition of phosphodiesterase. The negative inotropic effect of these agents, which is especially prominent when the level of extracellular Ca+ + is high,146 and which seems to be more prominent with caffeine than with theophylline,142 is difficult to explain on the basis of phosphodiesterase inhibition. Another manifestation of this "other" effect of the methylxanthines may be the contracture which was noted when these drugs were perfused through isolated rat hearts at low temperatures,147 an effect which was not seen with the catecholamines. Possibly this effect is related mechanistically to the contracture-producing effect of caffeine in skeletal muscle.'48 It may be noted that if an additional effect of the methylxanthines in the heart is eventually established, it will come as no surprise.
To illustrate this point, we might consider some of the known effects of caffeine on enzymes involved in liver glycogenolysis. In addition to its well-known effect on phosphodiesterase, caffeine is capable of inhibiting both adenyl cyclase and phosphorylase and also stimulates the activity of phosphorylase phosphatase. 1 The effects on adenyl cyclase and phosphorylase may not be important, since they are not prominent at concentrations which inhibit the phosphodiesterase markedly, but the stimulatory effect on phosphorylase phosphatase is pronounced at concentrations as low as 104M.15 This effect may occur in other tissues as well. For example, Hess and associates'49 noted that, while a low concentration of theophylline increased the phosphorylase-activating effect of epinephrine in the isolated rat diaphragm and had no effect by itself, a higher concentration reduced the percentage of phosphorylase in the a form and caused less potentiation of epinephrine than did the lower concentration. These effects of the higher concentration of theophylline most likely resulted from stimulation of phosphorylase a phosphatase activity.
Our fourth criterion has not been established. The increases in cardiac output and heart rate which occur in dogs and humans in response to the injection of cyclic AMP cannot be regarded as conclusive, because of the possibility that these could have been indirect effects.'02 Our inconsistent results with the isolated perfused working rat heart were mentioned previously. Studies with labeled cyclic AMP led to the conclusion that in the rat heart the nucleotide did not accumulate intracellularly to any significant extent. 104 Possible therapeutic approaches involving cyclic AMP might be directed at three levels: (1) the stimulation or inhibition of defective adenyl cyclase activity; (2) the stimulation or inhibition of a defective phosphodiesterase activity; and (3) the bypassing of the cellular mechanisms regulating cyclic AMP levels by providing exogenous compounds which either mimic or inhibit the actions of cyclic AMP on cellular processes.
An example of a disease which might involve a lesion at the level of cyclic AMP is bronchial asthma.166 In this instance the use of such agents as isoproterenol and theophylline seems well directed at the basic disorder, which may involve a decreased sensitivity to agents which normally tend to increase cyclic AMP levels in bronchial smooth muscle or a supersensitivity to agents which tend to decrease the level of cyclic AMP, or both.
In addition to the well-documented clinical use of catecholamines and methylxanthines in asthma, some measurements of cyclic AMP in the lung have been made. An epinephrinesensitive adenyl cyclase system has been iden- (table 2) . While this sort of evidence is unsatisfactory because of the heterogeneity of lung and our lack of information about the cell types in which cyclic AMP levels are changing, it does add some support to the hypothesis that bronchial asthma is due to a maladjustment of the cyclic AMP mechanism in bronchiolar muscle.
In certain other cases the recognition that cyclic AMP is involved may lead to the more rational and widespread use of theophylline and other phosphodiesterase inhibitors as therapeutic agents. For example, Breckenridge and associates167 have suggested that theophylline might be usefully employed in the treatment of myasthenia gravis, and clinical studies in this direction will be awaited with interest. It would be desirable to have agents which are more specific than the methylxanthines as phosphodiesterase inhibitors, and efforts to develop such agents are currently being made by several pharmaceutical firms.
Several other disorders which might involve faulty regulation of cyclic AMP levels come to mind. For example, since cyclic AMP represents a key regulator of steroidogenesis, it seems possible that certain endocrine disorders involving adrenal or gonadal dysfunction might be related to a primary defect at the level of cyclic AMP in the defective endocrine gland. One 
Concluding Remarks
Evidence has been presented to show that cyclic AMP is a second messenger mediating a variety of hormonal responses, including the positive inotropic response to the catecholamines. Our conclusion that the latter response is mediated by cyclic AMP must remain tentative because consistent inotropic effects in response to exogenous cyclic AMP have not been obtained. However, all of the available evidence, some of which we have reviewed in this paper, is compatible with this hypothesis. Whether it will be possible in the future to devise an isolated heart preparation which will be readily and reproducibly accessible to cyclic AMP and which will at the same time retain its ability to contract and relax remains to be seen.
Although cyclic AMP stands as the only well-established second messenger to date, data supporting such a role for cyclic GMP have been obtained. The existence of this nucleotide in urine has already been mentioned, and recently its formation in cardiac tissue has been studied. One interesting finding which has emerged from these studies is that cyclic AMP and cyclic GMP are apparently produced as the result of separate enzymes, which are affected differently by hormones and other factors. These data will be discussed in detail in a forthcoming publication. ' 
